Noxopharm Ltd.ASX: NOX

Noxopharm 2026 AGM Chair's Address

· Issued by Noxopharm Ltd. via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The address highlights the company's progress, including the completion of a clinical safety trial for its autoimmune drug candidate, SOF-SKN, which is set to enter testing on lupus patients soon. Additionally, the company is advancing its cancer program and has received recognition for its research published in a leading scientific journal. The Chair expresses gratitude to shareholders for their support, particularly during a recent capital raise, and emphasizes the company's potential for future achievements.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Noxopharm 2026 AGM Chair’s Address Sydney, 17 November 2026: Innovative biotech company Noxopharm Limited (ASX:NOX) provides Noxopharm Non-Executive Chairman Mr Frederick Bart’s address to the 2026 Annual General Meeting of Shareholders. -ENDS- About Noxopharm Noxopharm Limited (ASX:NOX) is a...

Noxopharm Ltd. on 6ix

In the deck

Earlier from Noxopharm

Later from Noxopharm

All Noxopharm news releases